Literature DB >> 1433525

Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.

M Connors1, A B Kulkarni, C Y Firestone, K L Holmes, H C Morse, A V Sotnikov, B R Murphy.   

Abstract

In previous studies, it was observed that children immunized with a formalin-inactivated respiratory syncytial virus vaccine (FI-RSV) developed severe pulmonary disease with greater frequency during subsequent natural RSV infection than did controls. During earlier efforts to develop an animal model of this phenomenon, enhanced pulmonary histopathology was observed after intranasal RSV challenge of FI-RSV-immunized cotton rats. Progress in understanding the immunologic basis for these observations has been hampered by the lack of reagents useful in manipulating the immune response of the cotton rat. This problem prompted us to reinvestigate the characteristics of immunity to RSV in the mouse. In the present studies, extensive pulmonary histopathology was observed in FI-RSV-immunized or RSV-infected BALB/c mice upon RSV challenge, and studies to determine the relative contributions of CD4+ or CD8+ T cells to this process were undertaken. Mice previously immunized with FI-RSV or infected with RSV were depleted of CD4+, CD8+, or both T-cell subsets immediately prior to RSV challenge, and the magnitude of inflammatory cell infiltration around bronchioles and pulmonary blood vessels and into alveolar spaces was quantified. The magnitude of infiltration at each anatomic site in previously FI-RSV-immunized or RSV-infected, nondepleted animals was similar, indicating that this is not a relevant model for enhanced disease. However, the effect of T-cell subset depletion on pulmonary histopathology following RSV challenge was very different between the two groups. Depletion of CD4+ T cells completely abrogated pulmonary histopathology in FI-RSV-immunized mice, whereas it had a much smaller effect on mice previously infected with RSV. FI-RSV-immunized or RSV-infected animals depleted of CD8+ T cells had only a modest reduction of pulmonary histopathology. In addition, RSV infection induced high levels of major histocompatibility complex class I-restricted cytotoxic T-cell activity, whereas FI-RSV immunization induced a low level. These data indicate that immunization with FI-RSV induces a cellular immune response different from that induced by RSV infection, which likely played a role in enhanced disease observed in infants and children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433525      PMCID: PMC240452     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.

Authors:  R M Chanock; R H Parrott; M Connors; P L Collins; B R Murphy
Journal:  Pediatrics       Date:  1992-07       Impact factor: 7.124

2.  Primary pulmonary murine cytotoxic T lymphocyte specificity in respiratory syncytial virus pneumonia.

Authors:  R Gupta; J W Yewdell; R A Olmsted; P L Collins; J R Bennink
Journal:  Microb Pathog       Date:  1990-07       Impact factor: 3.738

3.  Reinfection of mice with respiratory syncytial virus.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Med Virol       Date:  1991-05       Impact factor: 2.327

4.  Virus-specific delayed-type hypersensitivity (DTH). Cells mediating lymphocytic choriomeningitis virus-specific DTH reaction in mice.

Authors:  D Moskophidis; L Fang; J Gossmann; R Drjupin; J Löhler; M Bruns; F Lehmann-Grube
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

5.  The development of Balb/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface.

Authors:  B F Fernie; E C Ford; J L Gerin
Journal:  Proc Soc Exp Biol Med       Date:  1981-05

6.  Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

Authors:  M Connors; P L Collins; C Y Firestone; A V Sotnikov; A Waitze; A R Davis; P P Hung; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

7.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

Authors:  F W Henderson; A M Collier; W A Clyde; F W Denny
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

8.  Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.

Authors:  F Vaux-Peretz; J M Chapsal; B Meignier
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

Authors:  M Connors; A B Kulkarni; P L Collins; C Y Firestone; K L Holmes; H C Morse; B R Murphy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice.

Authors:  R J Brideau; M W Wathen
Journal:  Vaccine       Date:  1991-12       Impact factor: 3.641

View more
  104 in total

1.  Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

Authors:  K Bendelja; A Gagro; A Bace; R Lokar-Kolbas; V Krsulovic-Hresic; V Drazenovic; G Mlinaric-Galinovic; S Rabatic
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein.

Authors:  A H Brandenburg; L de Waal; H H Timmerman; P Hoogerhout; R L de Swart; A D Osterhaus
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.

Authors:  Jie Yang; Chen Ma; Yu Zhao; Anjing Fan; Xiufen Zou; Zishu Pan
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

4.  Fixing a failed vaccine.

Authors:  Steven M Varga
Journal:  Nat Med       Date:  2009-01       Impact factor: 53.440

5.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

6.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction.

Authors:  M F Bachmann; H Hengartner; R M Zinkernagel
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.